Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F133 - Advances in Lasers and Light Sources: What's the Truth?

Monday, February 19; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Summarize the most current indications and advanced treatment pearls and protocols for laser and light treatments.
  • Identify the most appropriate candidates for laser and device treatments, optimal settings, and gain treatment tips to take back to your office.
  • Describe state of the art and controversies in new vascular lasers, tattoo removal, body contouring, feminine rejuvenation and new emerging devices and techniques for use in both medical and aesthetic dermatology

Description

Advances in Lasers and Light Sources: What's The Truth is designed for dermatologists with a solid foundation of laser-tissue interaction to explore new and innovative devices. World class device experts with both clinical and research experience will impart the latest information on new vascular laser, pigmented lesions, laser assisted drug delivery, radiofrequency, body contouring, wrinkles, female rejuvenation, and tattoo removal to improve clinical outcomes and patient satisfaction. We will showcase the state of the art laser emerging techniques, devices, and controversies. This cutting-edge session will offer pearls to improve patient outcomes and pitfalls to avoid complications in your practice.

Disclosures

  • Alexiades, Macrene, MD, PhD: Allergan, Inc – A(H); Alma Lasers – I(Grants/Research Funding); DEKA – I(Grants/Research Funding); DUSA Pharmaceuticals – I(Grants/Research Funding); Lancome – I(Grants/Research Funding); Syneron Candela – I(Grants/Research Funding);
  • Anderson, Richard Rox, MD: Cytrellis Biosystems, Inc – C(SO); Living Proof, Inc. – C(SO); Massachusetts General Hospital – E(IP); MOE Medical Devices LLC – C(H); Olivio Laboratories, LLC – A(SO); Photomedex – C(H); Seven Oaks – C(IP); Seventh Sense BioSystems – C(SO); Sofregen Medical, Inc. – C(SO); Strata Skin Sciences – C(H);
  • Geronemus, Roy G., MD: Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(Grants/Research Funding); Cutera, Inc. – I(Grants/Research Funding); Cynosure, Inc – A(Grants/Research Funding), I(Grants/Research Funding); Cytrellis Biosystems, Inc – I(ST), SH(ST); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – I(Grants/Research Funding); Syneron Candela – A(Grants/Research Funding), I(Grants/Research Funding);
  • Haedersdal, Merete, MD, PhD: Ellipse Technology – O(EQ); Galderma Laboratories, LP – I(Grants/Research Funding); Leo Pharma A/S – I(Grants/Research Funding); Lutronics, Inc. – I(Grants/Research Funding); Procter & Gamble Company – C(Grants/Research Funding); Sciton, Inc. – O(EQ); Sebacia, Inc. – I(Grants/Research Funding); Syneron Candela – O(EQ);
  • Kauvar, Arielle N.B., MD: Allergan, Inc – A(H); Lumenis – C(Fees); Sebcaia, Inc – C(Fees); Syneron, Inc. – I(Grants/Research Funding);
  • Kilmer, Suzanne L., MD: Allergan, Inc – I(Grants/Research Funding); Cutera, Inc. – I(Grants/Research Funding); Cynosure, Inc. – I(Grants/Research Funding); Cytrellis Biosystems, Inc – A(Grants/Research Funding); Galderma USA – A(H); Lumenis – I(Grants/Research Funding); Lutronics, Inc. – I(Grants/Research Funding); Merz Aesthetics – I(Grants/Research Funding); Miramar Labs – A(H); R2 Dermatology, Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Sienna Labs, Inc. – A(H); Solta Medical – I(Grants/Research Funding); Syneron Candela – A(Grants/Research Funding); Zarin Medical – A(H); Zeltiq Aesthetics – A(H); Zift Medical – A(H);
  • Waibel, Jill S., MD: Alma Lasers – SP(H); Aquavit Pharmaceuticals – I(SO); Candela Corporation – SP(H); Cutera, Inc. – I(Grants/Research Funding); Lumenis – I(H); Lutronics, Inc. – I(Grants/Research Funding); Michelson Diagnostics Ltd. – I(EQ); Regenx – C(Grants/Research Funding); Sciton Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Vivosight – I(Grants/Research Funding); Zeltiq Aesthetics – SP(H);
Schedule
Monday, February 19
1:00 PM
Dr. Waibel / Introduction
1:06 PM
Dr. Geronemus / Rosacea, telangiectasia and vascular lesions: whats new
1:21 PM
Dr. Kauvar / Pigmented lesions: new strategies to optimize results
1:36 PM
Dr. Kilmer / Non-invasive fat removal: Devices and injectables
1:51 PM
Dr. Haedersdal / Laser Assisted Drug Delivery: Update, Challenges, Opportunities
2:06 PM
Dr. Alexiades / Radiofrequency from head to toe
2:21 PM
Dr. Waibel / Emerging Laser and Device Therapies
2:36 PM
Dr. Anderson / New Horizons in Tissue Fractions: Lasers and devices
2:51 PM
All faculty / Q&A
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 3:00 PM
  • Location
    Room 28D
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Jill S. Waibel, MD, FAAD
Speakers
  • Arielle N.B. Kauvar, MD, FAAD
  • Macrene Alexiades, MD, PhD, FAAD
  • Merete Haedersdal, MD, PhD
  • Richard Rox Anderson, MD, FAAD
  • Roy G. Geronemus, MD, FAAD
  • Suzanne L. Kilmer, MD, FAAD